VKTX — Viking Therapeutics Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$30.27
Market Cap$3.56B
Float113.3M
Shares Outstanding116.1M
vs. Analyst Target+205.0% to analyst PT
Dividend RateNone
Analyst Target Price$92.33 (19 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $10,731 -$39.5M $10,731 $3.8M
2021 $10,701 -$55.0M -$296,000 -$55.4M
2022 N/A -$68.9M -$291,000 -$70.1M
2023 N/A -$85.9M -$292,000 -$101M
2024 N/A -$110M -$346,000 -$151M
2025 N/A -$360M -$431,000 -$393M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$65.6M
Sep 2025 N/A -$90.8M
Dec 2025 N/A -$158M
Mar 2026 N/A -$158M

Ownership & Float

Insider Ownership2.8%
Institutional Ownership63.6%
Short Float20.0%
% of All Funds Holding4.64%
Number of Funds Holding381

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$32.91Near-term / short-term trend
Weekly40-Week SMA$32.68Medium-term trend
Weekly80-Week SMA$33.38Cyclical trend (business cycle)
Weekly200-Week SMA$30.38Secular trend (multi-year)
Monthly10-Month SMA$32.03Near-term monthly trend
Monthly20-Month SMA$34.33Medium-term monthly trend
Monthly40-Month SMA$35.40Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$26.40 support 1.10x 6 months ago
$24.20 support 1.22x 12 months ago
$73.00 resistance 1.21x 17 months ago

Historical Earnings Reactions (45 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.26% 0.00% 42.22% 17.04% -15.65%
1 Day 1.92% -0.48% 48.89% 28.31% -11.24%
1 Week 3.66% 4.95% 55.56% 30.11% -18.80%
2 Weeks 4.01% 3.15% 62.22% 52.86% -34.35%
1 Month 6.24% -0.16% 50.00% 174.10% -49.03%

Next earnings: April 29, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-0.7%45.5%11
Feb22.1%54.5%11
Mar-3.5%27.3%11
Apr1.4%45.5%11
May7.9%27.3%11
Jun-2.2%36.4%11
Jul1.6%54.5%11
Aug1.2%45.5%11
Sep5.4%27.3%11
Oct5.2%36.4%11
Nov-1.8%45.5%11
Dec14.3%54.5%11

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.26% 45.7% 519
Tuesday -0.02% 41.7% 571
Wednesday 0.06% 47.6% 569
Thursday 0.53% 46.9% 559
Friday 0.27% 49.0% 557

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 63.6%

Insider Transactions — Smart Summary

Total insider ownership: 2.8%

Founder-led management: Brian Lian (President, CEO & Director)

12-Month Insider Activity Summary

Total Filings12
Net Value-$14.1M
Net Shares Change176,677
% of Float0.2%
C-Suite Filings10
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
Lian Brian President and CEO -$9.1M 2 2 sell
Mancini Marianna Chief Operating Officer -$2.2M 3 3 sell
ZANTE GREG Chief Financial Officer -$2.2M 3 3 sell
FOEHR MATTHEW W -$508,414.4 1 1 sell
Aubuchon Neil William Chief Commercial Officer +$149,912.5 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-07-03 – 2025-07-03 3 3 -$984,533.73 3 C-suite
2025-10-28 – 2025-10-28 4 4 -$3.9M 3 C-suite
2026-01-05 – 2026-01-05 4 4 -$12.0M 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-10 Aubuchon Neil William Chief Commercial Officer +$149,912.5 Transaction at $33.50, now -9.6%
2026-01-05 ZANTE GREG Chief Financial Officer -$1.9M Transaction at $32.90, now -8.0%
2026-01-05 Lian Brian President and CEO -$7.7M Transaction at $32.96, now -8.1%
2026-01-05 Mancini Marianna Chief Operating Officer -$1.9M Transaction at $32.98, now -8.2%
2026-01-05 FOEHR MATTHEW W -$508,414.4 Transaction at $19.22, now +57.5%
2025-10-28 ZANTE GREG Chief Financial Officer -$216,480.567 Transaction at $35.00, now -13.5%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Viking Therapeutics Inc (VKTX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for VKTX on Trend Edge →